Skip to content
Hair Pipeline
← Back to the pipeline

Brepocitinib

A dual TYK2 and JAK1 inhibitor, hitting two kinases where the approved drugs hit one family.

Phase 2OralJAK inhibitor
Developed by
Priovant Therapeutics
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Partners
pfizer
Indications
Alopecia areata
Also known as
PF-06700841
Last public activity
May 2026
Record confidence
Medium

Why it matters

It sits between deucravacitinib's selectivity and a classic pan-JAK's breadth, which is the trade the whole class is arguing about. Originated at Pfizer and now developed by Priovant; the alopecia areata work is investigator-led rather than a company registrational programme, so read the phase with that in mind.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT05076006Phase 2COMPLETED

    Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

    Emma Guttman · n=51 · May 2021

  • NCT02974868Phase 2COMPLETED

    Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

    Pfizer · n=142 · December 2016

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources